pdufa.bio
HomeReadouts › September 2026

September 2026 clinical-trial readouts

Updated ยทnext FDA decision on the calendar
trial-readout estimates for September 2026, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.
← August 2026October 2026 →
32 readouts
AVIR · Sep 2026 (est.)
Bemnifosbuvir-Ruzasvir: HEPATITIS C VIRUS CHRONIC INFECTION
Awaiting dataupdated 7mo ago
ARVN · Sep 2026 (est.)
ARV-471: Breast Cancer
Awaiting dataupdated 5mo ago
ARQT · Sep 2026 (est.)
Topical Roflumilast: Hidradenitis Suppurativa
ARDX · Sep 2026 (est.)
Tenapanor: Irritable Bowel Syndrome With Constipation (IBS-C)
Awaiting data
GILD · Sep 2026 (est.)
Sacituzumab Govitecan: Non-small Cell Lung Cancer
EXEL · Sep 2026 (est.)
Cabozantinib: RCC
CORT · Sep 2026 (est.)
Relacorilant: Nonalcoholic Steatohepatitis (NASH)
Awaiting data
CGEM · Sep 2026 (est.)
CLN-081: Multiple Myeloma
Awaiting dataupdated 9mo ago
BHVN · Sep 2026 (est.)
Taldefgrobep Alfa: Obesity
Awaiting data
KPTI · Sep 2026 (est.)
Selinexor: Myelofibrosis
Awaiting data
IRON · Sep 2026 (est.)
DISC-1459: Erythropoietic Protoporphyria (EPP)
Awaiting data
APGE · Sep 2026 (est.)
APG777: Asthma
Awaiting dataupdated 4mo ago
GPCR · Sep 2026 (est.)
aleniglipron: Obese
Awaiting data
VERA · Sep 2026 (est.)
Atacicept: IgA Nephropathy (IgAN)
VNDA · Sep 2026 (est.)
VSJ-110: Dry Eye
SUPN · Sep 2026 (est.)
SPN-812: Attention-Deficit/Hyperactivity Disorder
Awaiting dataupdated 12mo ago
SNDX · Sep 2026 (est.)
Revumenib: Idiopathic Pulmonary Fibrosis
Awaiting data
SLN · Sep 2026 (est.)
SLN124: Polycythemia Vera
Awaiting dataupdated 6mo ago
AGMB · Sep 2026 (est.)
AGMB-129: Fibrostenotic Crohn's Disease
WVE · Sep 2026 (est.)
WVE-210201: Alpha-1 Antitrypsin Deficiency
Awaiting data
MRK · Sep 2026 (est.)
Pembrolizumab: Metastatic Triple-Negative Breast Cancer
BMY · Sep 2026 (est.)
Bevacizumab: Advanced Solid Tumors
BIIB · Sep 2026 (est.)
Litifilimab: Lupus Erythematosus, Systemic
MLTX · Sep 2026 (est.)
Sonelokimab: Hidradenitis Suppurativa
Awaiting data
OCGN · Sep 2026 (est.)
OCU410ST: Stargardt Disease
Awaiting data
ILMN · Sep 2026 (est.)
18F-MFBG: Parkinson Disease (PD)
IBRX · Sep 2026 (est.)
ALT-803: Non-muscle Invasive Bladder Cancer
Awaiting data
ALEC · Sep 2026 (est.)
AL001: Alzheimer's Disease
Awaiting dataupdated 7mo ago
EXEL · Sep 2026 (est.)
Cabozantinib: High Grade Neuroendocrine Neoplasms
CCCC · Sep 2026 (est.)
Cemsidomide: Multiple Myeloma
Awaiting data
BIIB · Sep 2026 (est.)
Litifilimab: Lupus Erythematosus, Systemic
IMMP · Sep 2026 (est.)
eftilagimod alfa: Solid Tumors
Awaiting dataupdated 4mo ago
Looking for an approval probability for these? We deliberately don't publish one. Here's why, and what we show instead (verified history + base rates).